R&D Pipeline
FibroGen is dedicated to creating innovative, first-in-class medicines for the treatment of chronic and life-threatening or debilitating conditions such as anemia in chronic kidney disease (CKD), chemotherapy induced anemia (CIA), Duchenne muscular dystrophy (DMD), and locally advanced pancreatic cancer. The products we develop represent more than isolated opportunities or single indications — we see our products as representing broader platforms that enable us to continue to investigate discrete pathways and mediators that are central to multiple diseases.
HIF Platform
Preclinical
Phase 1
Phase 2
Phase 3
Approved
ROXADUSTAT (HIF-PHI) ANEMIA OF CKD*
Approved
Phase 3
China
ROXADUSTAT (HIF-PHI) ANEMIA IN CIA
EVRENZO , 爱瑞卓
TM
®
*Currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and patients not on dialysis.
PARTNERED
Fibrotic Disease Platform
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Phase 2
Locally Advanced Pancreatic Cancer
Duchenne Muscular Dystrophy
PAMREVLUMAB
(ANTI-CTGF ANTIBODY)
Phase 3
Phase 3
WHOLLY-OWNED
Early Development
Pipeline
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Phase 3
Additional Programs
Various Indications
FG-3165
(ANTI-GAL-9 ANTIBODY)
Solid Tumors/AML
FG-3175
(ANTI-CCR8 ANTIBODY)
Solid Tumors
FG-3246 (FOR46)
(CD46-TARGETING ADC)
Metastatic Castration-Resistant
Prostate Cancer (mCRPC)
Phase 1
Preclinical
Preclinical
Preclinical
IN LICENSED
WHOLLY-OWNED
Pamrevlumab
Pamrevlumab, our proprietary fully human antibody, represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body.
Roxadustat
Roxadustat, an oral medicine, is the first in a new class of medicines, HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin; improved iron absorption and mobilization; and downregulation of hepcidin.
Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority.